Home・Akcijų sąrašas・Galectin Therapeutics Inc

Galectin Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.97 -1

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.94

Max

3.16

Pagrindiniai rodikliai
By Trading Economics
Pajamos	454K -5M
Pelnas, tenkantis vienai akcijai	-0.08
Darbuotojai	9
EBITDA	474K -3M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+270.37% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-12

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	77M 223M
Ankstesnė atidarymo kaina	3.97
Ankstesnė uždarymo kaina	2.97

Naujienos nuotaikos

By Acuity

25%

75%

73 / 340 reitingas Healthcare

Galectin Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-03 19:46; UTC

Galectin Therapeutics Inc is higher today, continuing an upward trend since Friday's close, despite pulling back from a session high. No specific news was identified.

2026-07-31 21:51; UTC

Galectin Therapeutics Inc is lower in after-market trading, influenced by broader market trends. The asset has faced three consecutive sessions of declines.

2026-07-30 20:10; UTC

Galectin Therapeutics Inc is lower today, breaking a trend of higher daily closes. Increased market volume accompanies the decline amid broader market volatility.

2026-07-29 18:58; UTC

Galectin Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close. The stock remains below its 20-day moving average.

2026-07-28 17:46; UTC

Galectin Therapeutics Inc shares are lower today, continuing a decline since Monday's close, amid broader market caution following significant drops in Asian indices.

2026-07-27 16:32; UTC

Galectin Therapeutics Inc shares are lower today, reflecting a notable decline since Friday. The stock has seen unusually high trading volume amid broader market sentiment.

2026-07-24 20:02; UTC

Galectin Therapeutics Inc is lower today, marking its ninth consecutive session of declines. The stock remains below its 20-day moving average.

2026-07-22 19:01; UTC

Galectin Therapeutics Inc. shares are trading lower, following a peak earlier in the session. High trading volume indicates increased investor activity.

2026-07-21 17:16; UTC

Galectin Therapeutics Inc. shares are lower today, continuing a five-session decline and trading significantly below the 20-day moving average. No specific news was identified.

2026-07-20 20:06; UTC

Galectin Therapeutics Inc shares are lower today, continuing a trend of five consecutive daily declines amid broader market volatility linked to geopolitical tensions.

Akcijų palyginimas

Kainos pokytis

Galectin Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

270.37% į viršų

12 mėnesių prognozė

Vidutinis 11 USD 270.37%

Aukščiausias 11 USD

Žemiausias 11 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Galectin Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Galectin Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

73 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.